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ABSTRACT
Background:
This study aimed to evaluate the severity of intraoperative and post-operative 
complications of gastric cancer surgery and to investigate the predictive factors 
correlated to surgical morbidity.
Methods:
We included 145 patients operated for gastric cancer. We investigated the risk factors 
associated with complications, length of hospital stay, operative time, and intraoperative 
blood transfusion (BT). Significant risk factors were analyzed by multiple logistic 
regression analysis.
Results:
Postoperative complications occurred in 32 patients (22.1 %) and the rate of major 
complications was 7.6%. The rate of anastomotic fistula was 6.9% and was correlated to 
diabetes, tumor size, operative time, surgical margin, and extended lymphadenectomy. 
The mean risk factors for postoperative morbidity were the presence of comorbidities 
and ASA score (p = 0.021), intraoperative BT (p = 0.045) and prolonged operative time 
(p = 0.055).
Conclusion:
Surgical morbidity of gastric cancer is correlated to the extent of resection as well as the 
clinical and histological characteristics.
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Management of gastric cancer has undergone in the last 
decade remarkable progress both in the neo-adjuvant 
and adjuvant treatments and in the surgical procedure 
as regards the extent of resection and the lymph node 
dissection. These advances are certainly associated 
with an improvement in the overall prognosis of the 
neoplastic disease. But this gain has been associated 
with over- morbidity and mortality that we need to 
know to prevent it. The rate of postoperative morbidity 
reported by the largest randomized controlled series 
varies from 11 to 46%.[1] This significant variability in 
the literature is explained not only by the differences 
in the characteristics of the studied populations, the 
therapeutic procedures but also by the definition of 
the morbidity used in each study. Thus, to limit the 
subjectivity in the analysis of the complications, many 
authors used the Clavien and Dindo classification of 
postoperative complications published in 2004. This 
classification seems more straightforward, objective, but 
above all reproducible, since it evaluates the severity 
of the complications according to their therapeutic 
management.[2] This study aimed to assess the severity 
of intraoperative and postoperative complications of 
gastric surgery and to investigate the predictive factors 
correlated to surgical morbidity.
Methods
Approval to conduct this study was obtained from 
the Institutional Review Board of the Salah Azaiz 
Institute. We conducted a retrospective study including 
145 patients with histologically proven gastric 
adenocarcinoma who underwent curative or palliative 
gastrectomy from January 2005 to December 2015. Non-
inclusion criteria were as follows:(1) metastatic disease, 
(2) other synchronous tumoral location, (3) unknown 
surgery status, (4) unknown vital status; (5) incomplete 
pathological data.
After institutional review board approval, we collected 
patient and tumor-related factors through medical 
records: age, sex, BMI, proteinemia (hypoproteinemia 
was defined as less than 60g/dl), the hemoglobin level, 
comorbidities, and American Society of Anesthesiologist 
(ASA) score, tumor size, depth of invasion and the stage 
of gastric cancer according to the eighth edition of the 
American Joint Committee on Cancer TNM classification 
system.
The surgical variables included the type of procedure 
(total versus partial gastrectomy), the extent of lymph 
node dissection (D0, D1.5, and D2) based on the 
Japanese Gastric Cancer Treatment Guidelines 2010 
(version 3)[3] and the number of retrieved lymph nodes 
(NRLN), multivisceral organ resection (MVR), operative 
time measured from the first skin incision to the closure 
of all skin incisions and confirmed by the attending 
anesthesiologist in the operating room, intraoperative 
allogeneic blood transfusion and the length of hospital 
stay. 
The extent of the lymphadenectomy was based on 
the individual surgeon’s judgment. Splenectomy was 
performed in cases of metastatic lymph nodes at the 
hilum of the spleen or because of iatrogenic injury. The 
extent of stomach resection was related to the primary 
tumor site: total gastrectomy was performed in all 
proximal tumor locations and total gastric tumors, and 
subtotal gastrectomy was performed for distal tumor 
locations, provided that a 5 to 6-cm safety margin was 
present. A multi-visceral resection was performed 
in all cases of T4 or suspected T4 tumors. After total 
gastrectomy, reconstruction was made by Roux-en-Y 
esophagojejunostomy. Esophago-jejunal anastomoses 
were performed by hand-suture or mechanically 
with a circular stapler according to the surgeon’s 
choice. The stapled esophageal and jejunal doughnuts 
were examined for completeness of anastomosis. A 
hand-sutured or stapler Billroth II followed subtotal 
gastrectomy. A prophylactic antibiotic of a second- or 
third-generation cephalosporin was administered to 
all patients and usually lasted for 5 days following the 
operation.
The integrity of the anastomosis was routinely evaluated 
on the seventh postoperative day by a water-soluble 
contrast swallow and/or by ingestion of methylene blue 
before reintroducing an oral intake. The anastomotic 
fistula was diagnosed with extravasation of contrast 
product during radiological examination and/or with 
discharge or gastrointestinal content through a drain. 
Clinical leakage was defined as the presence of either 
clinical symptoms suggesting potential leakages such as 
abdominal pain abnormal with drain discharge, fever, 
and leukocytosis.
Postoperative morbidity and mortality included all 
adverse events reported within the first 30 days after 
surgery or during the same hospitalization, and late 
complications were not included in this study. Surgical 
complications included anastomotic fistula and 
leakage, early anastomotic stenosis, septic collection, 
and wound infection, pleural effusion, ileus, and 
bleeding. Non-surgical complications were heart 
failure, pneumonia or respiratory failure, urinary 
tract infection, decompensation of diabetes, and 
thromboembolic events. All complication data were 
graded retrospectively according to the Clavien-Dindo 
classification from Grade 1 to Grade 5 according to the 
treatment for each complication. Major complications 
included all complications classified as grade III A or 
more according to the Clavien Dindo system.
Statistical analysis
The categorical variables were presented as numbers 
and percentages. Continuous variables were expressed 
as the mean ± standard Deviation (SD) with ranges, 
and groups were compared using the Test t of Student. 
Moreover, some continuous variables were converted to 
dichotomous variables for convenience, including the 
age (≤65 years versus > 65 years), the body mass index 
BMI (<20 kg/m2 versus ≥ 20kg/m2), hemoglobin rate 
(≤10 g/dl versus >10 g/dl), the tumor size (<50mm 
versus≥50 mm) and the NRLN (≤15, 16-25 and≥25). 
Clinical and pathological data were compared between 
patients to analyze the major risk factors associated with 
complications, length of hospital stay, operative time 
and intraoperative blood transfusion. The groups were 
compared using the chi-square test or Fisher’s exact 
test. All variables with a p-value <0.2 in the univariate 
analysis were entered into a multivariate analysis using 
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a logistic regression model to identify independent 
factors of perioperative blood transfusion and operative 
time. We used the Statistical Package for Social Science 
(SPSS), version 20.0 for Windows, and ap-value less than 
0.05 was considered significant.
Results
The clinicopathological characteristics of the patients are 
summarized in Table 1. There were 93 males (64%) and 
52 females (36 %), with a mean age of 61.48 years±12.86 
(range, 26 to 85 years) and 44 patients (49.5%) were more 
than 70 years old.
The operative data are summarized in Table 2. Total 
gastrectomy was performed in 77 patients (53.1%) and 
subtotal gastrectomy in 68 patients (46.9%). Combined 
organ resection was performed in 34 (23.4 %) patients. D1 
lymph node dissection was carried out in 15 cases, and 
extended lymphadenectomy in 130 patients (89.7%) from 
which 36 patients (24.8%) had D1.5 lymphadenectomy 
and 94 patients had D2 lymphadenectomy.
The Mean operative time was 194 minutes ± 53.22 
with extremes ranging from 110 to 350mn. Univariate 
analysis of the factors influencing the operating time 
is shown in Table 3. The mean operative time was 
significantly increased in patients with proximal and 
middle third tumors compared with distal tumors 
(208.81mm vs 181.42mn respectively, p=0.002). Tumor 
staged T3-T4 required a longer operative time compared 
to pT1-T2 tumors (199.81mnvs 178.85mn respectively, 
p=0.032). We also found that the mean operative 
time was significantly longer with total gastrectomy 
compared to partial gastrectomy (204.16mnvs 182.56mn 
respectively, p=0.015), multi-organ resection (215mn 
vs 187.60mn, p=0.021), D2 dissection compared to D1 
/ D1.5 dissection (204.02mm vs 188.61mn respectively, 
p= 0.004) and in case of splenectomy or spleno-
pancreatectomy (p = 0.037). On multivariate analysis 
extended lymphadenectomy and combined organ 
resection were the only independent factors associated 
with a longer operative time.
Intraoperative blood transfusion was performed in 77 
patients (53.1%), with a mean amount of 2.14 units and 
extremes ranging from 1 to 4 units. Of the transfused 
patients, 19 patients (24.7%) required more than three 
units. Univariate analysis of factors associated with 
intraoperative blood transfusion is shown in table4. 
Transfused patients had a longer mean operative time 
compared to non-transfused patients (23.04mn vs 
183.83mn, p=0.054). Significant factors on the univariate 
analysis were included in the multivariate analysis 
(Table4). Tumor location and combined organ resection 
were found to be the independent risk factors of 
intraoperative blood transfusion.
A total of 113 out of 145 (77.9%) patients had no 
complications, and 32 (22.1%) had at least one medical 
or surgical complications. Details of postoperative 
complications are listed in Table 2. Eighteen patients 
(12.4%) had one or more medical complications of which 
seven patients had significant medical complications. 
They were dominated by postoperative pneumonia 
occurring in 13 cases (9%) and pulmonary embolism in 
2 cases (1.4%).
Surgical complications occurred in 18 patients within a 
delay of 10 days (range, 4 to 20 days). The anastomotic 
fistula was the most common surgical complication 
occurring in 10 cases (6.9%), and postoperative 
peritonitis secondary to complete anastomotic leakage 
was diagnosed in only one patient. From the 145 
patients, four (2.8%) required re-laparotomies for serious 
complications: one case of stenosis of the esophago-
jejunal anastomosis, one case of anastomotic leakage, 
one case of the esophago-jejunal fistula with major 
ionic disorders and severe dehydration, and one case 
of a deep abdominal abscess that was not accessible to 
percutaneous radiologic drainage.
Using the Clavien-Dindo classification, the 32 
complicated patients had the following grades: 21 
patients (14.5%) had grade II, 3 patients (2.1%) had 
grade IIIa, 2 patients (1.4%) had grade IIIB and one 
(1.6%) had grade IVa. Postoperative death (grade V of 
Clavien-Dindo classification) occurred in five patients 
(3.4%) within a mean delay of 30 days after surgery 
(range 18 to 74 days). Three patients died because of 
anastomotic fistula, one patient died after reoperation 
for anastomotic stenosis and the last patient died from 
respiratory failure secondary to pneumonia. 
Univariate analysis of clinical and therapeutic predictive 
factors of postoperative complications is shown in Table 
5. We found that the mean risk factors for postoperative 
morbidity were the presence of comorbidities (p = 
0.021), intraoperative blood transfusions (p = 0.045) and 
prolonged operative time (p = 0.055). Hypoproteinemia 
at diagnosis seems to increase morbidity (28.8% vs 18.3%, 
p = 0.066). Patients with BMI greater than or equal to 20 
had a higher rate of complications than those with a BMI 
of less than 20 (23.3% vs. 20.8%, p = 0.842). However, 
we found that age, gender, locally advanced tumors, 
extended lymphadenectomy, splenectomy or SPC, 
total gastrectomy, and combined organ resection were 
not significantly associated with higher postoperative 
morbidity.
The mean length of postoperative hospital stay was 
15.08 days ± 7.48 (range 7-74 days). Univariate analysis 
of factors associated with the length of hospital stay is 
represented in Table 6. No significant difference was 
found in the period of hospital stay according to the 
extent of gastrectomy and lymphadenectomy. However, 
the duration of hospitalization was significantly 
increased in patients with comorbidities regardless 
of age and gender (p= 0.017). Patients who presented 
postoperative complications had a more extended 
hospital stay (p <0.001). According to Clavien-Dindo 
classification, the length of hospital stays progressively 
increased from non-complicated patients to grade V 
patients (P<0.0001). The duration of hospitalization is 
extended by 13.99 days (p = 0.03) in case of anastomotic 
fistula and by 6.17 days (p = 0.004) in cases of respiratory 
infections.
The results of the univariate analysis of patient-related 
risk factors of fistula and leakage showed that these 
complications were more frequent in diabetic patients 
(23.5% vs 4.7%; p=0.004). According to laboratory 
variables, preoperative hypoproteinemia (11.5% in case 
of hypoproteinemia vs 4.3% with normal proteinemia, 
p=0.168) and anemia with hemoglobin rate less than 
10 g/dl (12.5 % vs 4.8%, p=0.139) were likely to be 
associated 
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with a higher rate of fistula even if the difference was not 
statistically significant. In the analysis of tumor-related 
factors, anastomotic fistula was significantly associated 
with tumor size exceeding 50mm (10.3% vs 1.7%, 
p=0.045), gastric walls rigidity (33.8% vs 5.1%; p=0.016), 
and the length of the proximal margin of resection (the 
mean length of the proximal margin in patients with 
fistula was 41± 24.358 mm vs 57.55± 26.008, p=0.042). 
When analyzing surgical related factors, we found that 
the type of gastrectomy, the extent of lymphadenectomy, 
and combined organ resection were not significantly 
associated with a more frequent fistula. Nevertheless, 
the number of retrieved lymph nodes (23.24 ± 11.036 
vs 27.5 ± 12.059 in case of anastomotic fistula, p=0.073), 
as well as the duration of the operation (190.77 ± 12.59 
min vs 238±16.96 min in case of fistula, p=0.006), were 
identified as predictive factors of fistula.
Table 1: Clinical and histological patients’ characteristics 
 
Table 1 : Clinical and histological patients’ characteristics  
Variables N % 
Age (mean, ±DS, min, max, ans) 61.48 ±12.86 (26-85) 
 ≥70 years 44 30.3 
<70 years 101 69.7 
Gender Male 93 64 
Female 52 36 
BMI (mean± SD,kg/m2) 19.906 ±2.719 [12.48-28.02]  
<20kg/m2 72 49.7 
≥20 kg/m2 73 50.3 
Hypoproteinemia No 93 64.1 
Yes 52 35.9 
Hb (g/dl) ≤10g/dl 40 27.6 
>10g/dl 105 72.5 
Comorbidities No 101 69.7 
Yes 44 30.3 
ASA score < ASA 3 119 82. 
≥ ASA 3 26 17.9 
Tumor location Upper third 21 14.5 
Middle third 45 31 
Distal third 77 53.1 
Pangastric tumor 2 1.4 
Tumor size 
 (mean ±DS, min, max, mm) 
                                                     
64.86 ±34.49 [12-220mm] 
<50mm 58 40 
≥ 50mm 87 60 
Lauren Classification  
 
 
Intestinal  109 75.2 
Mixed 4 2.8 
Diffuse                                                 32 22.1 
Differenciation                              Well 63 43.4 
Meanly 47 32.4 
Poorly/undifferenciated 35 24.2 
LVI No 73 50.3 
Yes 72 49.7 
PNI No 76 52.4 
Yes 69 47.6 
pT stage pT1 8 5.5 
pT2 32 22.1 
pT3 61 42.1 
pT4 44 30.3 
LN status N- 26 17.9 
N+ 119 82.1 
pN stage pN0 26 17.9 
pN1 31 21.4 
pN2 41 28.3 
pN3a 28 19.3 
pN3b 19 13.1 
NRLN (mean ±DS, min, max) 23.63 ± 10.856 [5-57 ganglions] 
<15  27 18.6 
15-24  61 42.1 
≥25  57 39.3 
NMLN (mean ±DS, min, max) 8.16 ±7.854 [1-38 ganglions] 
 LNR LNR0 26 17.9 
LNR1 25 17.2 
LNR2 30 20.7 
LNR3 64 44.2 
UICC stage I 16 11 
II 45 31 
III 77 53 
IV 7 5 
Resection R0 136 93.8 
R1 8 5.5 
R2 1 0.7 
Treatment sequency Surgery alone 47 32.4 
CT-Sur -CT/RTCT 13 9 
Sur+CT ADJ 27 18.6 
SUR+ RTCT/RT ADJ 58 40 
CT: chemotherapy, ADJ: adjuvant, RTCT/RT: radio-chemotherapy or adjuvant radiation therapy, SUR: surgery, LVI: 
lympho-vascular invasion, PNI: perineural invasion, NRLN: number of retrieved lymph nodes, NMLN: number of 
metastatic lymph nodes 
LNR : lymph nodes ratio, SD : standard deviation 
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Table 2: Surgical and postoperative features of patients 
Table 2 :  Surgical and postoperative features of patients 
Variables N Rate 
Gastrectomy 
Total gastrectomy  77 53.1% 
Partial gastrectomy 68 46.9% 
Combined organ resection 34 23.4% 
Transverse mesocolon resection 12 8.3% 
Transverse colectomy  5 3.4% 
Small bowel resection 4 2.8% 
Liver  1 0.7% 
Cholecystectomy 1 0.7% 
Cephalic duodenopancreatectomy 1 0.7% 
SPC 3 2.1% 
Splenectomy 11 7.6% 
Lymphadenectomy 
D1 15 10.3% 
D1.5 36 24.8% 
D2 94 64.8% 
Number of retrieved lymph nodes 
≤15 34 23.4% 
16-25 59 40.7% 
≥25 52 35.9% 
Intraoperative blood transfusion 
No 68 46.8% 
Yes 77 53.1% 
Operative time (mean ±SD, mn , range  ) 194mm ± 53.22 [110-350mn] 
Length of hospital stay (mean ±SD, days , range  ) 15.08 ±7.485 [7-74 days] 
Postoperative mortality 5 3.4% 
Total postoperative complications 32 22.1% 
Surgical complications   
Anastomotic fistula  10 6.9% 
Isolated duodenal fistula 1 0.7% 
Postoperative peritonitis: Anastomotic leakage 1 0.7% 
Deep abdominal collection 3 2.1% 
Parietal abscess 3 2.1% 
Anastomotic stenosis 2 1.4% 
Pleural effusion 2 1.4% 
Non surgical complications  
Respiratory infection 13 9% 
Pulmonary embolism 2 1.4% 
Cardiac failure 1 0.7% 
Urinary infection 1 0.7% 
Diabetic decompensation  1 0.7% 
Clavien-Dindo classification 
No complications 113 77.9% 
Grade II 21 14.5% 
Grade  IIIa 3 2.1% 
Grade IIIb 2 1.4% 
Grade Iva 1 0.7% 
Grade V 5 3.4% 
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Table 3: Univariate and multivariate analysis of factors influencing the operative time
Table 4: Univariate and multivariate analysis of clinical, therapeutic and histological factors associated with intraoperative blood 
transfusion
Table 3: Univariate and multivariate analysis of factors influencing the operative time 
Factors N Univariate analysis Multivariate analysis 
Operative time 
(Mean ± SD,  mn) 
P* Exp B 
95% CI 
P 
Tumor location     0.002 - - 
Distal 77 181.42±52.897 
Others 68 208.31±50.480 
Tumor size (mm)                                                                        0.256 - - 
≥50 87 197.15±53.625 
<50 58 187.84±52.733 
Depth of invasion 0.034 -0.196 
[-5.413-32.511] 
0.160 
T1-T2 40 178.85±49.207 
T3-T4 105 199.81±53.918 
Gastrectomy        0.015 - - 
PG 68 182,56 ± 56,130 
TG 77 204,16 ± 48,878 
MVR           0.021 - - 
No 111 187,60 ± 49,186 
Yes 34 215 ± 61,62 
Splenectomy/ Splenopancreatectomy 0.037 0.287 
[22.158 – 80.997] 
0.001 
No 132 189.57 ± 75.622 
Yes 14 235.71 ± 75.622 
Lymphadenectomy  0.004 -0.196 
[-39.918, -3.756] 
0.018 
D1/D1.5 51 188,61 ± 56,130 
≥ D2 94 204,02 ± 39,586 
TG: total gastrectomy, PG : partial gastrectomy, MVR: multivisceral resection 
* test T of Student, SD : standard deviation 
CI: confidence interval 
 
Table 4: Univariate and multivariate analysis of clinical, therapeutic and histological factors 
associated with intraoperative blood transfusion 
Variables N        Univariate analysis Multivariate analysis 





 60.64±12.88 62.23±12.89 0.692† - - 
Gender 0.864* - - 
Male 93 43 (46.2%) 50 (53.8%) 
Female 52 25 (48.1%) 27 (51.9%) 
BMI 
(mean± SD,kg/m2) 
145 20.039±2.79 19.78±2.66 0.164† - - 




Distal 77 44 (57.1%) 33 (42.9%) 
Others 68 24 (35.3%) 44 (67.7%) 
Gastrectomy      0.007* - NS 
TG 77 28 (36.4%) 49 (63.6%) 
PG 68 40 (58.8%) 28 (41.2%) 
MVR 0.001* 0.267 
[0,131-0.497] 
0.001 
No 111 61(55%) 50 (45%) 
Yes 34 7 (20.6%) 27(79.4%) 
Splenectomy/ Splenopancreatectomy 0.002* - NS 
No 131 67 (51.1%) 64 (48.9%) 
Yes 14 1 (7.1%) 13 (92.9%) 
Lymphadenectomy  0.728* - - 
D1 15 9 (60%) 6 (40%) 
D1.5 36 13 (31.6%) 23 (63.9%) 
D2 94 46 (48.9%) 48 (51.1%) 
Operative time 
(mean± SD, mn) 
145 183.82 203.04 0.054† - NS 
NRLN 0.042*  0,132 
[-0,016-0.189] 
0,097 
≤15 34 21(61.8%) 13(38.2%) 
16-25 59 27(48.8%) 32 (54.2%) 
≥25 52 20 (38.5%) 32(61.5%) 
Depth of invasion                        0.116* - - 
T1/T2 40 23 (57.6%) 17 (42.5%) 
T3/T4 105 45 (42.9%) 60 (57.1%) 
Tumor size  
(mean±SD, mm) 
145 51.16±27.62 71.66±38.48 0.027† - NS 
BMI: Body mass index, TG: total gastrectomy, PG : partial gastrectomy, MVR: multivisceral 
resection, NRLN: number of retrieved lymph nodes. BT: blood transfusion 
† test T of Student.  
* test chi2 Pearson 
SD: standard deviation 
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Table 5: Univariate analysis of predictive factors of postoperative complications
Table 6: Univariate analysis of factors associated with the length of hospital stay
Table 5 : Univariate analysis of predictive factors of postoperative complications 
Variables N Postoperative complications P 
Value 
Yes No 
Age (mean, years) 145 61,16 ± 12,67 62,66 ±13,70 0.563† 
BMI (kg/m2)                                   <20                                  72 57 (79.2%) 15(20.8%) 0.842* 
≥20 73 56(76.3%) 17 (23.3%) 
Proteinemia (mean, g/l) 145 61,72 ± 7,83 58,88 ±7,093 0.066* 
 Hypoproteinemia             No                                                         93 76 (81.7%) 17 (18.3%) 
Yes  52 37 (71.2%) 15 (28.8%) 
Hemoglobin level (g/dl)  145 10,74 ± 1,75 10,62 ± 2,09 0.750† 
ASA score <ASA3 119 96 (80,7%) 23 (19,3%) 0.089* 
≥ASA3 26 17 (65,4%) 9 (34,6%) 
Comorbidities No 101 84 (83,2%) 17 (16,8%) 0.021* 
Yes 44 29 (65,9%) 15 (34,1%) 
Blood transfusion No 68 58 (85,3%) 10 (14,7%) 0.045* 
Yes 77 55 (71,4%) 22 (28,6%) 
Splenectomy/ 
Splenopancreatectomy   
No 131 103 (78,6%) 28 (21,2%)  
0.537* Yes 14 10 (71.4%) 4 (28.6%) 
LND                                                               D1 15 12 (80%) 3 (20%) 0.838* 
D1.5/D2 130 101 (77.7%) 29 (22.3%) 
MVR No 111 87 (78,4%) 24 (21,6%) 0.814* 
Yes 34 26 (76,5%) 8 (23,5%) 
Gastrectomy TG 77 56 (72,7%) 21 (27,3%) 0.108* 
PG 68 57 (83,8%) 11 (16,2%) 
Operative time (mn) 145 189,50 ± 51,50 210 ±57,36 0.055† 
Tumor size  
(mean, mm) 
≥50mm 58 46(79.3%) 12 (20.7%) 0.744* 
<50mm 87 67(77%) 20(23%) 
Depth of invasion      T4        44 34(77.3%) 10 (22.7%) 0.9* 
T1-T2-T3 101 79 (78.2%) 22 (21.8%) 
Tumor location                            Distal              77 62 (80.5%) 15 (19.5%) 0.424* 
Others 68 51 (75%) 17 (25%) 
BMI: Body mass index, TG: total gastrectomy, PG : partial gastrectomy, MVR: multivisceral 
resection, LND: lymph node dissection 
† test T of Student.  
* test chi2 Pearson 
 
Table 6 : Univariate analysis of factors associated with the length of hospital stay 
Factors N Length of hospital stay 
(mean, days) * 
P 
Age (years)                         
                                          
≤65 90 14.41 ± 5.538 0.172 
>65                           55 16.16 ± 9.845 
Gender                                                                   Men 93 14.49 ± 7.933 0.369 
Women 52 14.33 ± 6.618 
Comorbidities                No 101 13.81± 5.096 0.017 
Yes 44 17.98 ±10.717 
Gastrectomy                                           PG 68 15.61 ± 4.719 0.381 
TG 77 14.47 ± 9.719 
MVR No 111 14.95 ± 8.157 0.707 
Yes 34 15.5 ± 4.737 
Splenectomy/ 
Splenopancreatectomy   
No 131 15.02 ± 7.781 0.145  
Yes 14 15.57 ± 3.857 
Lymphadenectomy  D1/D1.5 51 14.52 ± 8.32 0.227 
D2 94 16.1 ± 5.54 
Postoperative 
complications                                          
No 113 12.58 ± 2.856 <0.001 
Yes 32 23.91 ± 11.292 
Grade Clavien Dindo No 113 12.58 ± 2.856 <0.001 
II 21 20.43 ± 4.664 
IIIa 3 26 ± 8.544 
IIIb 2 30 ± 14.142 
Iva 1 20 
V 5 35 ± 23.082 
Fistula                                         No 135 14.11 ± 5.186 0.03 
Yes 10 28.10 ±17.136 
 Respiratory infection              No 132 14.52 ± 7.457 0.004 
Yes 13 20.69 ±5.266 
TG: total gastrectomy, PG : partial gastrectomy, MVR: multivisceral resection 
* test T of Student.  
 




In our study, the rate of postoperative complications 
was 22.1% which seems consistent with the data in 
the literature.[1] However, we found a lower rate of 
major complications according to Clavien and Dindo 
classification (7.6%), and this can be explained not 
only by the small number of the patients but also by a 
retrospective classification of complications based on 
data collected from medical records. The most common 
complications reported in the literature are respiratory 
complications occurring in 1.1% to 12.32% of cases[4], 
decompensation of chronic disease, and gastroparesis.
 Anastomotic leakage occurring in 1 to 11.5%, intra-
abdominal abscesses, pancreatic fistulas, intraperitoneal 
hemorrhages, postoperative occlusions, postoperative 
pancreatitis, and eviscerations were the most common 
surgical complications.[5, 6] However, Marrelli reported 
a higher rate of intra-abdominal infection of 14.2% with 
more extensive lymph node surgery.[7] In this study, we 
reported a rate of 9% of pneumonia, 6.9% of anastomotic 
fistula, and 4.2% of suppurative complications. 
According to Baiocchi, the postoperative mortality 
rate was also very variable. Western centers reported 
a mortality rate of 5%, while Eastern centers reported a 
lower rate of 2%.[1] In our series, postoperative deaths 
occurred in 3.4% of cases within an average of 30 days 
after the intervention, which seemed consistent with the 
literature data.
The extent of surgical resection, particularly the type 
of gastrectomy and lymphadenectomy, represent the 
most crucial factor of postoperative morbidity in gastric 
cancer. 
Many studies evaluated the impact of extended 
lymphadenectomy on perioperative morbidity and 
mortality and the results were variable between the Asian 
series, particularly Japanese, and the Western series 
(Table 7). Two large randomized Western multicenter 
trials compared D1 and D2 lymphadenectomy: The 
British MRC ST01 study, conducted by Cuschieri[8, 9] 
and the  Dutch trial conducted by Bonenkamp[10, 11] 
reported that D2 lymphadenectomy was associated 
with an increased rate of morbidity and included and 
a longer hospital stay. These two trials were included 
in a Cochrane meta-analysis[12] showing that D2 lymph 
node dissection had tripled the rate of mortality with a 
relative risk of 2.93 (95% CI= 1,45-3.45) and concluded 
that the “excess mortality” of the D2 lymphadenectomy 
was related not only to spleno-pancreatectomy but 
also to the learning curve of the surgeons. However, 
several other randomized studies such as the German 
multicenter prospective study conducted by Siewert 
who had shown that D2 lymphadenectomy retrieving 
more than 25 lymph nodes was not significantly 
correlated with additional morbidity and mortality.
[13] Although many studies reported a significant 
gain in survival with a D2-D3 lymphadenectomy,  this 
extended lymph node dissection was associated to 
a higher rate of postoperative complications with a 
longer hospital stay, longer operative time and higher 
rate of blood transfusion.[14-16] However, the Japanese 
prospective study of Takeshi Sano et al. found that the 
incidence of serious complications was not different in 
the two groups.[17] Several reports have reported that 
splenectomy did not provide survival benefits and 
described a higher postoperative morbidity rate with 
and without splenectomy[18, 19], especially infectious 
complications[18] such as intra-abdominal abscess and 
pulmonary infections[20] and concluded that the use of 
prophylactic splenectomy to remove macroscopically 
negative lymph nodes near the splenic hilum in patients 
undergoing total gastrectomy for proximal gastric cancer 
should be avoided. However, in other randomized 
studies, D2 lymphadenectomy with splenectomy was not 
correlated to postoperative morbidity and mortality as 
well as the length of hospital stay and operative time.[17, 
21, 22] In our series, no significant difference in duration 
of hospitalization or overall postoperative complication 
was found according to the extent of lymphadenectomy. 
Although splenectomy and left pancreatectomy exposed 
to a higher risk of complications (28.6% vs 21.4%), the 
difference was not statistically significant (p = 0.537) with 
a comparable length of hospital stay. Our results can be 
explained by the low proportion of splenectomy and left 
pancreatectomy (7.6% and 2.1% respectively) and by the 
selection of patients for extensive lymphadenectomy 
who were younger and with an ASA sore <3. However, 
in our study, extended lymphadenectomy led to an 
increased intraoperative morbidity with more blood 
transfusion and longer operative time.
Several studies investigated the impact of the type of 
gastrectomy on postoperative morbidity and mortality 
with variable results. In fact, since the extent of the 
gastrectomy depended on the site of the tumor and 
its size, most of the studies had essentially compared 
total gastrectomy to partial gastrectomy in distal 
tumors. These studies were included in a recent meta-
analysis published in 2016 by Qi et al.[23], combining 
data from 5447 patients included in 10 retrospective 
studies and one prospective randomized study. In this 
meta-analysis, TG was associated with a higher risk of 
postoperative complications (RR = 1.76, 95% CI = 1.31-
2 .36, p = 0.0002) and especially more frequent intra-
abdominal abscesses (RR = 3.41, 95 % CI = 1.21-9.63, p 
<0.05) compared to partial gastrectomy with a similar 
rate of postoperative mortality (RR = 1.48, 95% CI = 
0.90-2.44, p = 0.12). Moreover, the impact of the type 
gastrectomy on morbidity and mortality, regardless of 
the tumor location, has been reported in several other 
studies suggesting that TG is associated with higher rates 
of postoperative complications and morbidity, such as 
the Dutch trial (OR = 2.04, 95% CI = 1.01-3.79, p = 0.02). 
In the analysis of surgical morbidity and mortality of 
the Randomized “Critics” trial where 636 patients were 
included, total gastrectomy and oesophago-gastrectomy 
were independent risk factors for both surgical and 
medical postoperative complications (OR = 1.88, 95% 
CI = 1.30-2.72, p = 0.001) with higher rates of surgical 
revision and longer hospital stay.[24] Nakagawa et al. 
performed a retrospective analysis of the risk factors of 
postoperative complications in 539 patients who were 
previously prospectively collected.[25]
In this study, total gastrectomy was the only independent 
factor of high-grade complications according to the 
Clavien and Dindo classification (OR = 2.075, 95% CI 
= 0.26-0.896, p = 0.021). However, several other studies 
had reported comparable morbidity rates between the 
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two surgical procedures. Indeed, the retrospective 
study of Park et al.[26] involving 719 patients did not 
report a significant difference between GT and GP 
regarding postoperative morbidity (19.3% versus 13.6% 
respectively, p = 0.103). However, Persiani found that 
the length of hospital stay exceeding ten days was 
particularly observed with total gastrectomy.[27] 
These results support the data from our series, where 
postoperative morbidity was not significantly correlated 
with the type of gastrectomy with a comparable rate 
of fistula and length of hospital stay even though the 
incidence of complications appeared to be higher in 
case of GT (27.3%) compared to GP (16.2%). However, 
TG was associated with higher perioperative morbidity 
with and increased rate of blood transfusion (63.6% vs 
41.2%, p= 0.007) which is consistent with the results 
of the meta-analysis of Sun et al.[28] and also a longer 
operative time (210mn vs 189.5mn, p= 0.015) which is 
consistent with the results of Gockel et al. and Papenfuss 
et al.[29, 30]
The benefit of multivisceral resection (MVR) for locally 
advanced gastric ADK is controversial because of the 
increased mortality and morbidity. In the systematic 
review carried out by Brar[31] including 17 studies with 
1343 patients, the morbidity rate varied between 11.8% 
and 90% and perioperative mortality ranged from 0 to 
15%. In contrast, in our study, MVR did not significantly 
increase the rate of postoperative complications (23.5% 
vs 21.6%, p = 0.814) and fistula (11.8% vs. 5.4%, p = 0.245) 
but was correlated to higher intraoperative morbidity 
with a significant lengthening of the operative time 
and an increase of blood transfusion requirement. Our 
findings were similar to that of the large multicenter and 
observational study published by Pacelli in 2013, who 
found that MVR was not associated with an increase in 
mortality (p = 0.55) or morbidity (33.9% vs 31.6%, p = 
0.38).[32]
The impact of intraoperative blood transfusions on 
Table 7: Randomized trials comparing the impact of the extent of lymphadenectomy on surgical morbidity and mortality  T ble 7: Randomized trials comparing the impact of the extent of lymphadenectomy on surgical 
morbidity and mortality   
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short-term and long-term outcomes has been widely 
debated. In our study, blood transfusion had led to a 
significant increase in the rate of complication and fistula. 
Indeed, many authors had identified blood transfusions 
as an independent risk factor of major complications[30, 
33] and supported the hypothesis that allogeneic blood 
transfusions induced immunosuppression that might 
increase the risk of infectious complications and leading to 
an extension of hospital stay.[34] Otherwise, in this study, 
transfused patients had a longer mean operation time 
than non-transfused patients (203.4 minutes vs183.82mn 
respectively, p=0.054), and the same results were also 
reported by Xiao et al.[34]  and Ojima et al.[35] We also 
found that postoperative complication was correlated 
to the duration of surgical procedure and we stated that 
patients who developed an anastomotic fistula had a 
significantly longer operative time (238 min vs 190.77 min, 
p = 0.006) which is consistent with the results of the study 
of Migita et al.[5] who reported a significant correlation 
between anastomotic leakage and the duration of the 
surgical procedure (330 min vs 290 min, p = 0.0416)  and 
the finding of Nakagawa et al. who reported that operating 
time exceeding 240mn was a risk factor for high-grade 
complications.[25]
Several intrinsic factors of postoperative morbidity of 
gastric cancer have been reported in the literature such as 
age, sex, nutritional status, and co-morbidities as well as 
tumor characteristics. The impact of gender and hormonal 
status on postoperative morbidity and mortality remains 
controversial. Although our results as well as those of 
Persiani et al.[27], Nakagawa et al.[25] and Lee et al.[36] 
did not support the correlation between gender and 
postoperative morbidity and mortality,  the results of 
Critics trial[24] as well the 15-year results of the Dutch 
trial[37] have shown that men were exposed to a higher 
risk of post-operative complications and death. On the 
other hand, Sah et al. stated that women aged between 46 
to 56 years were significantly predisposed to a higher risk 
of postoperative complications suggesting that hormonal 
instability related to menopausal status could result 
in a change of the host’s response to stress and surgical 
trauma.[38]
Malnutrition can lead to the abnormal function of 
macrophages, neutrophils, and lymphocytes, which can 
inhibit the immune response and increase the surgical 
morbidity[39] and the incidence of major postoperative 
complications according to Clavien Dindo classification.[36] 
In the recent study by Zheng et al. including 1976 patients, 
the group of malnourished patients with hypoproteinemia 
(412 patients) had a significantly higher complication 
rate (21.4% vs 15.5%, p = 0.005).[40] Although we only 
recorded the level of proteinemia, we found that patients 
with hypoproteinemia had a higher rate of complications 
(28.8% vs 18.3%, p=0.066) and fistula (11.5% vs 4.3%, p = 
0.168). Obesity (BMI> 25)  is frequently associated with 
other co-morbidities such as diabetes, cardiovascular 
and respiratory diseases and according to The Japanese 
study by Ojima T, overweight patients had a longer 
duration of intervention and a higher rate of postoperative 
complications (anastomotic release, pancreatic fistula).
[41] However, in our series, postoperative complications 
were not significantly increased in patients with a BMI 
greater than 20 kg/m2. These findings are comparable to 
those of several other studies which had not objectified 
a correlation between the weight of the patients and the 
specific surgical complications, and which had identified 
hypoalbuminemia as the only independent factor of 
morbidity.[25, 42]
Although in the studies by Persiani et al., Gil-Rendo et 
al., and Nakagawa et al., morbidity and mortality were 
correlated neither to age nor to co-morbidities and ASA 
score, but to the extensive surgery[25, 27, 43], other studies 
including that of Papenfuss reported that the implication 
of age as a factor of morbidity and mortality would 
most probably be related to the increased incidence of 
comorbidities with higher ASA score after 60 years and 
the alteration of the immune mechanisms.[30] In our 
series, the age of patients was not identified as a risk factor 
for morbidity even though we found that the average age 
of patients who died postoperatively was 75 years (range, 
65-84 years). However, we found that postoperative 
complications were more frequent in the case of 
comorbidities with a higher rate of anastomotic fistula in 
diabetic patients and a longer duration of hospitalization. 
The predictive morbidity value of the ASA score in our 
study was similar to that of Lee et al. who reported a linear 
increase of surgical morbidity with ASA score without 
significant difference (19.5% for ASA1, 24% for the ASA2, 
and 31.4% if the ASA score was greater than or equal to 3; 
p= 0.088).[36]
Some authors had identified clinical and histological 
features of gastric tumors as intrinsic risk factors for 
postoperative morbidity. It has been reported that 
morbidity and mortality were higher in the upper and 
middle third gastric tumors.[43] On the contrary, in our 
study, there was no difference regarding postoperative 
morbidity according to the tumor location (p=0.424). 
However, intraoperative morbidity was found to be 
higher in the proximal, middle, and total gastric tumors 
compared to distal tumors and the tumor site represents 
an independent risk factor of intraoperative blood 
transfusion. Also, the operative time was significantly 
shorter in distal tumors compared to other locations. These 
findings were like those of Yu et al. and Liu et al. who 
suggested that the incrimination of the proximal tumor 
site in postoperative morbidity would be more related 
to larger resections and more difficult anastomosis with 
more blood transfusion and longer operative time and not 
to the tumor location itself.[44, 45]
The correlation between the risk of postoperative 
complications and the tumor size can be explained by 
the fact that large tumors are associated with increased 
surgical technical difficulties, an extension of the type of 
gastrectomy, and the need for multi-visceral resections.
[33, 42] Contrariwise, in our study, we found no significant 
difference in terms of post complications according to the 
tumor size. However, when analyzing the specific surgical 
complications, we found that tumors larger than 50 mm 
were significantly associated to a higher rate of fistula 
and an increase of blood transfusion requirement which 
is supported by the finding of Wang et al. who divided 
513 patients into four groups according to the tumor size 
(≤2, ≤3, ≤5,> 5 cm) and stated that the rate of postoperative 
complications was comparable between the four groups 
(p = 0.682) with a significant increase in blood transfusion 
with larger tumor (30% for sizes ≤2, 33.7% 
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for sizes ≤3, 46.3% for sizes ≤5 and 63.9% for sizes> 5 
cm, p <0.001).[46] The majority of authors as well as 
our finding had not demonstrated a strong correlation 
between postoperative morbidity and tumor stage and 
the depth of parietal invasion even if locally advanced 
tumors would be particularly associated with larger 
resections and more frequent surgical difficulties.[23, 24, 
26, 27] However, we stated that surgery of T3-T4 tumors 
was associated with an increase of the intraoperative 
morbidity which was assessed by a longer operative 
time and more frequent blood transfusion supporting 
the results of Ojima et al. and Zhou et al.[35, 47]
Our study has some limitations not only its retrospective 
nature and the small number of included patients but also 
a lack of evaluation of the predictive factors of surgical 
mortality because of the low number of postoperative 
deaths.
Conclusion
Our study was able to analyze the intraoperative 
morbidity by determining the factors influencing the 
operative time and the intraoperative transfusions and 
suggested that it depends not only on the extent of the 
surgery and particularly the multi-visceral resections 
and the extension of the lymphadenectomy but also on 
the tumoral characteristics. In addition, the use of the 
Clavien and Dindo classification allowed an objective 
assessment of postoperative morbidity that depends on 
the patient’s terrain and the association of comorbidities 
and tumor characteristics. We also identified the 
predictive factors of an anastomotic fistula which 
represented the most severe complication. Moreover, 
the occurrence of complications and their grade was 
the determinant of the length of postoperative hospital 
stay. Further studies focusing on late complications, 
functional results, and quality of life are needed to 
improve the surgical outcomes.
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